Salivary Biomarkers for Detection of Oral Squamous Cell Carcinoma: Current State and Recent Advances

Current Oral Health Reports

Volumn 1, Issue 2, 2014, Pages 133-141

  Yakob, Maha ^a   Fuentes, Laurel ^a   Wang, Marilene B ^b   Abemayor, Elliot ^b   Wong, David T W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Exosomes; Metabolomics; Methylomics; Microbiomics; Oral cancer; Oral fluid diagnostics; Oral squamous cell carcinoma; Proteomics; Salivaomics; Salivary biomarker; Salivary diagnostics; Transcriptomics

Indexed keywords

EID: 84907876893     PISSN: None     EISSN: 21963002     Source Type: Journal    
DOI: 10.1007/s40496-014-0014-y     Document Type: Review

References (97)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. DOI: 10.3322/caac.21166
2. Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J. 2012;6:126–30. DOI: 10.2174/1874210601206010126
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;27(12):2893–917. DOI: 10.1002/ijc.25516
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. DOI: 10.3322/canjclin.55.2.74
5. Oral health in America: a report of the Surgeon General. J Calif Dent Assoc. 2000;28(9):685–695.
6. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87(1):14–32. DOI: 10.1177/154405910808700104
7. Zini A, Czerninski R, Sgan-Cohen HD. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med. 2010;39(4):299–305. DOI: 10.1111/j.1600-0714.2009.00845.x
8. Decker J, Goldstein JC. Risk factors in head and neck cancer. N Engl J Med. 1982;306(19):1151–5. DOI: 10.1056/NEJM198205133061905
9. Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S, et al. Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med. 2006;35(1):11–8. DOI: 10.1111/j.1600-0714.2005.00364.x
10. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(11):712–7. DOI: 10.1056/NEJM199503163321104
11. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 2008;37(1):1–10. DOI: 10.1111/j.1600-0714.2007.00579.x
12. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14(1):47–62. DOI: 10.1177/154411130301400105
13. Mücke T, Wagenpfeil S, Kesting MR, Hölzle F, Wolff KD. Recurrence interval affects survival after local relapse of oral cancer. Oral Oncol. 2009;45(8):687–91. DOI: 10.1016/j.oraloncology.2008.10.011
14. Sklenicka S, Gardiner S, Dierks EJ, Potter BE, Bell RB. Survival analysis and risk factors for recurrence in oral squamous cell carcinoma: does surgical salvage affect outcome? J Oral Maxillofac Surg. 2010;68(6):1270–5. DOI: 10.1016/j.joms.2009.11.016
15. Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-Perez J, Rodriguez-Campo FJ. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck. 2009;31(9):1168–80. DOI: 10.1002/hed.21088
16. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10(11):3607–13. DOI: 10.1158/1078-0432.CCR-03-0632
17. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol. 2002;161(3):1051–60. DOI: 10.1016/S0002-9440(10)64266-6
18. Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res. 2001;7(6):1523–32.
19. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4–5):309–16. DOI: 10.1016/j.oraloncology.2008.06.002
20. Peacock ZS, Pogrel MA, Schmidt BL. Exploring the reasons for delay in treatment of oral cancer. J Am Dent Assoc. 2008;139(10):1346–52. DOI: 10.14219/jada.archive.2008.0046
21. Chiappin S, Antonelli G, Gatti R, De Palo EF. Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta. 2007;383(1–2):30–40. DOI: 10.1016/j.cca.2007.04.011
22. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthetic Dent. 2001;85(2):162–69. DOI: 10.1067/mpr.2001.113778
23. Amerongen AV, Bolscher JGM, Veerman ECI. Salivary proteins: protective and diagnostic value in cariology? Caries Res. 2004;38(3):247-53. DOI: 10.1159/000077762
24. Liu J, Duan Y. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol. 2012;48(7):569–77. DOI: 10.1016/j.oraloncology.2012.01.021
25. de Almeida PV, Grégio AM, Machado MA, de Lima AA, Azevedo LR. Saliva composition and functions: a comprehensive review. J Contemp Dent Pract. 2008;9(3):72–80.
26. Dodds MWJ, Johnson DA, Yeh CK. Health benefits of saliva: a review. J Dent. 2005;33(3):223–33. DOI: 10.1016/j.jdent.2004.10.009
27. Mohamed R, Campbell JL, Cooper-White J, Dimeski G, Punyadeera C. The impact of saliva collection and processing methods on CRP, IgE, and myoglobin immunoassays. Clin Transl Med. 2012;1(1):19. DOI: 10.1186/2001-1326-1-19
28. Principe S, Hui ABY, Bruce J, Sinha A, Liu FF, Kislinger T. Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics. 2013;13(10–11):1608–23. DOI: 10.1002/pmic.201200533
29. Bigler LR, Streckfus CF, Copeland L, Burns R, Dai XL, Kuhn M, et al. The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med. 2002;31(7):421–31. DOI: 10.1034/j.1600-0714.2002.00123.x
30. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci. 2012;69(19):3341–50. DOI: 10.1007/s00018-012-1027-0
31. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DTW. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics. 2012;11(2):M111.012112. DOI: 10.1074/mcp.M111.012112
32. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, et al. Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One. 2009;4(6):e5875. DOI: 10.1371/journal.pone.0005875
33. Hu S, Gao K, Pollard R, Arellano-Garcia M, Zhou H, Zhang L, et al. Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res. 2010;62(11):1633–8. DOI: 10.1002/acr.20289
34. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78–95. DOI: 10.1007/s11306-009-0178-y
35. Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D, et al. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem. 2013;288(37):26888–97. DOI: 10.1074/jbc.M113.452458
36. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004;22(8):411–6. DOI: 10.1016/j.tibtech.2004.06.005
37. Silberring J, Ciborowski P. Biomarker discovery and clinical proteomics. Trends Anal Chem. 2010;29(2):128–40. DOI: 10.1016/j.trac.2009.11.007
38. Chen W, Samuelson FW, Gallas BD, Kang L, Sahiner B, Petrick N. On the assessment of the added value of new predictive biomarkers. BMC Med Res Methodol. 2013;13:98. DOI: 10.1186/1471-2288-13-98
39. Warnock DG, Peck CC. A roadmap for biomarker qualification. Nat Biotechnol. 2010;28(5):444–5. DOI: 10.1038/nbt0510-444
40. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol. 1992;166(4):375–81. DOI: 10.1002/path.1711660409
41. Akhter M, Hossain S, Rahman QB, Molla MR. A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. J Oral Maxillofac Pathol. 2011;15(2):168–76. DOI: 10.4103/0973-029X.84485
42. Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008;112(2):345–51. DOI: 10.1002/cncr.23183
43. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95(3):229–49.
44. Wong DT. Salivaomics. J Am Dent Assoc. 2012;143(10 Suppl):19S–24S. This paper coined the term salivaomics to reflect the important advancements in salivary diagnostics through the development of omics-based biomarkers. DOI: 10.14219/jada.archive.2012.0339
45. Dowling P, Wormald R, Meleady P, Henry M, Curran A, Clynes M. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. J Proteomics. 2008;71(2):168–75. DOI: 10.1016/j.jprot.2008.04.004
46. Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, et al. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2008;14(8):705–12. DOI: 10.1111/j.1601-0825.2008.01488.x
47. Denny P, Hagen FK, Hardt M, Liao LJ, Yan WH, Arellanno M, et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res. 2008;7(5):1994–2006. DOI: 10.1021/pr700764j
48. Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010;89(10):1016–23. DOI: 10.1177/0022034510380414
49. Bonne NJ, Wong DTW. Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med. 2012;4:82. DOI: 10.1186/gm383
50. Sorsa T, Tjaderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004;10(6):311–8. DOI: 10.1111/j.1601-0825.2004.01038.x
51. Stott-Miller M, Houck JR, Lohavanichbutr P, Mendez E, Upton MP, Futran ND, et al. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2628–36. DOI: 10.1158/1055-9965.EPI-11-0503
52. Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, et al. Salivary analysis of oral cancer biomarkers. Br J Cancer. 2009;101(7):1194–8. DOI: 10.1038/sj.bjc.6605290
53. Rusthoven KE, Raben D, Song JI, Kane M, Altoos TA, Chen CH. Survival and patterns of relapse in patients with oral tongue cancer. J Oral Maxillofac Surg. 2010;68(3):584–9. DOI: 10.1016/j.joms.2009.03.056
54. Korostoff A, Reder L, Masood R, Sinha UK. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol. 2011;47(4):282–7. DOI: 10.1016/j.oraloncology.2011.02.006
55. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008;14(19):6246–52. DOI: 10.1158/1078-0432.CCR-07-5037
56. de Jong EP, Xie HW, Onsongo G, Stone MD, Chen XB, Kooren JA, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS One. 2010;5(6):e11148. DOI: 10.1371/journal.pone.0011148
57. Jou Y-J, Lin C-D, Lai C-H, Chen C-H, Kao J-Y, Chen S-Y, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010;681(1–2):41–8. DOI: 10.1016/j.aca.2010.09.030
58. Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler DL, Love A, et al. The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem. 2003;278(19):17121–9. DOI: 10.1074/jbc.M212590200
59. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575–606. DOI: 10.1146/annurev.bi.58.070189.003043
60. Baird A, Walicke PA. Fibroblast growth factors. Br Med Bull. 1989;45(2):438–52.
61. Gorugantula LM, Rees T, Plemons J, Chen H-S, Cheng Y-SL. Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(2):215–22. DOI: 10.1016/j.oooo.2012.03.013
62. Vajaria BN, Patel KR, Begum R, Shah FD, Patel JB, Shukla SN, et al. Evaluation of serum and salivary total sialic acid and alpha-L-fucosidase in patients with oral precancerous conditions and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(6):764–71. DOI: 10.1016/j.oooo.2013.01.004
63. Li Y, St John MAR, Zhou XF, Kim Y, Sinha U, Jordan RCK, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004;10(24):8442–50. DOI: 10.1158/1078-0432.CCR-04-1167
64. Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, et al. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012;21(4):664–72. The study validated a panel of seven mRNAs and three proteins that previously were reported to be capable of discriminating patients with oral squamous cell carcinoma from healthy subjects in independent cohorts. DOI: 10.1158/1055-9965.EPI-11-1093
65. Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, et al. Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol. 2011;47(1):51–5. The study showed that the previously discovered and validated biomarkers were discriminatory and reproducible in a different ethnic cohort. DOI: 10.1016/j.oraloncology.2010.10.009
66. Ziober AF, Patel KR, Alawi F, Gimotty P, Weber RS, Feldman MM, et al. Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res. 2006;12(20):5960–71. DOI: 10.1158/1078-0432.CCR-06-0535
67. Yen CY, Chen CH, Chang CH, Tseng HF, Liu SY, Chuang LY, et al. Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. Biomarkers. 2009;14(4):244–9. DOI: 10.1080/13547500902829375
68. Jordan RCK, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger DG, Wong DTW, et al. Overexpression of matrix metalloproteinase-1 and-9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res. 2004;10(19):6460–5. DOI: 10.1158/1078-0432.CCR-04-0656
69. Lallemant B, Evrard A, Combescure C, Chapuis H, Chambon G, Raynal C, et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer. 2009;9:370. DOI: 10.1186/1471-2407-9-370
70. Zeng Y. Principles of micro-RNA production and maturation. Oncogene. 2006;25(46):6156–62. DOI: 10.1038/sj.onc.1209908
71. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet. 2007;8:215–39. DOI: 10.1146/annurev.genom.8.080706.092351
72. Liu C-J, Lin S-C, Yang C-C, Cheng H-W, Chang K-W. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34(2):219–24. DOI: 10.1002/hed.21713
73. Chang KW, Liu CJ, Chu TH, Cheng HW, Hung PS, Hu WY, et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dent Res. 2008;87(11):1063–8. DOI: 10.1177/154405910808701116
74. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15(17):5473–7. The presence of microRNA in saliva was demonstrated and approximately 50 miRNAs were detected in healthy saliva. Furthermore, significantly lower levels of miR-125a and mi-R200a were in the saliva from oral squamous cell carcinoma patients compared with healthy control subjects. DOI: 10.1158/1078-0432.CCR-09-0736
75. Spielmann N, Wong DT. Saliva: diagnostics and therapeutic perspectives. Oral Dis. 2011;17(4):345–54. DOI: 10.1111/j.1601-0825.2010.01773.x
76. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner ACR, Yu WH, et al. The human oral microbiome. J Bacteriol. 2012;192(19):5002–17. DOI: 10.1128/JB.00542-10
77. Glurich I, Acharya A, Shukla SK, Nycz GR, Brilliant MH. The oral-systemic personalized medicine model at Marshfield Clinic. Oral Dis. 2013;19(1):1–17. DOI: 10.1111/j.1601-0825.2012.01921.x
78. Pushalkar S, Ji X, Li Y, Estilo C, Yegnanarayana R, Singh B, et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. 2012;12:144. DOI: 10.1186/1471-2180-12-144
79. Pushalkar S, Mane SP, Ji X, Li Y, Evans C, Crasta OR, et al. Microbial diversity in saliva of oral squamous cell carcinoma. FEMS Immunol Med Microbiol. 2011;61(3):269–77. Microbial diversity was shown in saliva of oral squamous cell carcinoma (OSCC), as well as the presence of common phylotypes associated with OSCC or controls. The findings are of importance because they reflect the repopulation or shift in microbial communities. DOI: 10.1111/j.1574-695X.2010.00773.x
80. Marur S, D'Souza G, Westra WH, Forastiere A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9. DOI: 10.1016/S1470-2045(10)70017-6
81. Viet CT, Schmidt BL. Methylation array analysis of preoperative and postoperative saliva DNA in crab cancer patients. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3603–11. DOI: 10.1158/1055-9965.EPI-08-0507
82. Jithesh PV, Risk JM, Schache AG, Dhanda J, Lane B, Liloglou T, et al. The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer. 2013;108(2):370–9. This paper illustrates the application of epigenetic biomarkers and targets available to further the development of therapy in oral squamous cell carcinoma. DOI: 10.1038/bjc.2012.568
83. Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-Lopez L, Macia-Colon G, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res. 2011;4(7):1061–72. DOI: 10.1158/1940-6207.CAPR-11-0006
84. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9(2):280–99. DOI: 10.1007/s11306-012-0482-9
85. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263–9. DOI: 10.1038/nrm3314
86. Tripathi P, Kamarajan P, Somashekar BS, MacKinnon N, Chinnaiyan AM, Kapila YL, et al. Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. Int J Biochem Cell Biol. 2012;44(11):1852–61. DOI: 10.1016/j.biocel.2012.06.025
87. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1):R125–134. DOI: 10.1093/hmg/dds317
88. Ogawa Y, Miura Y, Harazono A, Kanai-Azuma M, Akimoto Y, Kawakami H, et al. Proteomic analysis of two types of exosomes in human whole saliva. Biol Pharm Bull. 2011;34(1):13–23. DOI: 10.1248/bpb.34.13
89. Ogawa Y, Kanai-Azuma M, Akimoto Y, Kawakami H, Yanoshita R. Exosome-like vesicles with dipeptidyl peptidase IV in human saliva. Biol Pharm Bull. 2008;31(6):1059–62. DOI: 10.1248/bpb.31.1059
90. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.
91. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006;137(3):313–21. DOI: 10.14219/jada.archive.2006.0180
92. Wei F, Patel P, Liao W, Chaudhry K, Zhang L, Arellano-Garcia M, et al. Electrochemical sensor for multiplex biomarkers detection. Clin Cancer Res. 2009;15(13):4446–52. DOI: 10.1158/1078-0432.CCR-09-0050
93. Gau V, Wong D. Oral fluid nanosensor test (OFNASET) with advanced electrochemical-based molecular analysis platform. Ann N Y Acad Sci. 2007;1098:401–10. DOI: 10.1196/annals.1384.005
94. Pujari M, Bahirwani S, Balaji P, Kaul R, Shah B, Daryani D, et al. Oral fluid nanosensor test: saliva as a diagnostic tool for oral health. J Calif Dent Assoc. 2012;40(9):733–6.
95. Wei F, Wong DT. Point-of-care platforms for salivary diagnostics. Chin J Dent Res. 2012;15(1):7–15.
96. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100(20):1432–8. DOI: 10.1093/jnci/djn326
97. Brinkman BMN, Wong DTW. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol. 2006;18(3):228–33. DOI: 10.1097/01.cco.0000219250.15041.f8